<DOC>
	<DOCNO>NCT01101464</DOCNO>
	<brief_summary>A trial compare one 15 mg tongue tablet equal three 5 mg tongue tablet Org 5222 ( asenapine ) subject schizophrenia schizoaffective disorder deliver .</brief_summary>
	<brief_title>A Trial Determine Whether Two Differing Strength Tablets ( 3 x 5 mg Versus 1 x 15 mg ) Sublingually Org 5222 ( Asenapine ) Are Safe Equal Subjects With Schizophrenia Schizoaffective Disorder ( P05937 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>must provide write informed consent scope nature investigation explain , sign trialrelated activity , include screen evaluation ; must least 18 less 65 year age ; either male female ; female must either surgically sterile , postmenopausal least 1 year , nonpregnant use method birth control acceptable investigator ; must able speak , read understand English able respond question follow simple instruction ; must diagnose screen interview accord Diagnostic &amp; Statistical Manual Mental Disorders , 4th edition ( DSMIV ) , nonfirst episode schizophrenia schizoaffective disorder ( 295.70 ) ; schizophrenia , must follow type : schizophrenia paranoid type ( 295.30 ) , schizophrenia disorganize type ( 295.10 ) , schizophrenia catatonic type ( 295.20 ) , schizophrenia undifferentiated type ( 295.90 ) , schizophrenia residual type ( 295.60 ) ; must discontinue use antipsychotic medication except depot neuroleptic least 3 day prior baseline . For depot neuroleptic , subject must complete 1 dose interval baseline interview ; must take experimental medication least 30 day prior baseline ; hypothyroidism , diabetes , high blood pressure , chronic respiratory condition consider candidate enrollment trial condition stable , receive standard therapy condition , prescribe dose regimen medication stable least 3 month , appropriate clinical laboratory parameter within clinically acceptable limit condition , must willing remain hospital minimum 14 day approximately 17 day ( minimum 3 maximum 7day washout period , minimum 8day inpatient period , possible 3day stabilization period , need , prior discharge ) . untreated uncompensated clinically significant renal , endocrine , hepatic , respiratory , cardiovascular , hematologic , immunologic , cerebrovascular disease , malignancy ; consider obese investigator ( e.g. , great 30 % ideal body weight ) ; seizure disorder take anticonvulsant prevent seizure ; clinically relevant electrocardiogram ( ECG ) abnormalities screen visit ( Day 2 ) baseline ( Day 0 ) ; history clinically significant cardiac event require resuscitation ; screen visit , admission trial , washout period baseline ( Day 0 ) , clinically significant abnormal laboratory , vital sign , physical examination finding , opinion investigator , would preclude trial participation ; require concomitant treatment hypnotic ( sleep induction ) chloral hydrate ≤3000 mg/day , Ambien ( zolpidem tartrate ) ≤10 mg qhs , ( agitation ) benzodiazepine lorazepam , ≤10 mg/day ; score great mild baseline ( score &gt; 2 ) item Abnormal Involuntary Movement Scale ( AIMS ) assessment screen and/or require ongoing treatment anticholinergic medication beyond baseline ( Day 0 ) ; history significant drug and/or alcohol abuse ( accord DSMIV criterion 305.00 ) within 30 day screen visit ; confirm positive result alcohol/drug screen test alcohol , illegal ( exclude marijuana ) , nonprescribed drug screen hospital admission ; primary psychiatric diagnosis ( accord DSMIV criterion ) schizophrenia schizoaffective disorder ; actively suicidal screen visit , become admission hospital , washout period , baseline ( Day 0 ) ; Clinical Global Impression ( CGI ) ( Severity Illness ) rating great moderately ill ( score &gt; 4 ) screening baseline ; noncompliant ( &gt; 25 % ) washout period ( include baseline Day 0 ) ; , pregnant , intend become pregnant course trial , currently nurse mother course trial . require concomitant medication substrate , inhibitor , inducer Cytochrome P450 CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>